266 related articles for article (PubMed ID: 21650079)
21. Results of a single-center, single-dose, randomized-sequence, open-label, two-way crossover bioequivalence study of two formulations of valsartan 160-mg tablets in healthy volunteers under fasting conditions.
Spínola AC; Almeida S; Filipe A; Neves R; Trabelsi F; Farré A
Clin Ther; 2009 Sep; 31(9):1992-2001. PubMed ID: 19843489
[TBL] [Abstract][Full Text] [Related]
22. Generic substitution: issues for problematic drugs.
Henderson JD; Esham RH
South Med J; 2001 Jan; 94(1):16-21. PubMed ID: 11213935
[TBL] [Abstract][Full Text] [Related]
23. Generic low-molecular-weight heparins: some practical considerations.
Fareed J; Leong WL; Hoppensteadt DA; Jeske WP; Walenga J; Wahi R; Bick RL
Semin Thromb Hemost; 2004 Dec; 30(6):703-13. PubMed ID: 15630677
[TBL] [Abstract][Full Text] [Related]
24. Bioequivalence requirements in the European Union: critical discussion.
García-Arieta A; Gordon J
AAPS J; 2012 Dec; 14(4):738-48. PubMed ID: 22826032
[TBL] [Abstract][Full Text] [Related]
25. Open questions on bioequivalence: an updated reappraisal.
Marzo A
Curr Clin Pharmacol; 2007 May; 2(2):179-89. PubMed ID: 18690864
[TBL] [Abstract][Full Text] [Related]
26. Modernization and Strengthening of Bioequivalence Guidelines in Japan.
Kuribayashi R; Yamaguchi T; Takagi K
Clin Pharmacokinet; 2021 Feb; 60(2):145-151. PubMed ID: 33247363
[TBL] [Abstract][Full Text] [Related]
27. Generic products of antiepileptic drugs: a perspective on bioequivalence and interchangeability.
Bialer M; Midha KK
Epilepsia; 2010 Jun; 51(6):941-50. PubMed ID: 20384761
[TBL] [Abstract][Full Text] [Related]
28. The Investigators' Brochure: a comparison of the draft international conference on harmonisation guideline with current Food and Drug Administration requirements.
Cocchetto DM
Qual Assur; 1995 Dec; 4(4):240-6. PubMed ID: 8890349
[TBL] [Abstract][Full Text] [Related]
29. [Bioequivalence studies of pharmaceutical preparations].
Vetchý D; Frýbortová K; Rabisková M; Danecková H
Cas Lek Cesk; 2007; 146(5):431-3. PubMed ID: 17554963
[TBL] [Abstract][Full Text] [Related]
30. [New guidelines for the assessment of bioavailability and bioequivalence].
Blume H; Schug B; Tautz J; Erb K
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2005 May; 48(5):548-55. PubMed ID: 15887065
[TBL] [Abstract][Full Text] [Related]
31. Overview of the European Medicines Agency's Development of Product-Specific Bioequivalence Guidelines.
Sullivan JO; Blake K; Berntgen M; Salmonson T; Welink J;
Clin Pharmacol Ther; 2018 Sep; 104(3):539-545. PubMed ID: 29319156
[TBL] [Abstract][Full Text] [Related]
32. Bioequivalence studies: a new EMA guideline.
Houin G
Arzneimittelforschung; 2010; 60(4):169-70. PubMed ID: 20486464
[No Abstract] [Full Text] [Related]
33. Regulatory Approaches and Considerations in Establishing Bioequivalence of Inhaled Compounds.
Mayers I; Bhutani M
J Aerosol Med Pulm Drug Deliv; 2018 Feb; 31(1):18-24. PubMed ID: 28708443
[TBL] [Abstract][Full Text] [Related]
34. Regulatory advice and drug development--a case study in negotiating with regulators.
Seldrup J
Stat Med; 2011 Jun; 30(13):1628-35. PubMed ID: 21365671
[TBL] [Abstract][Full Text] [Related]
35. Bioequivalence/bioavailability retention samples.
Ransom C
Qual Assur; 1993; 2(1-2):42-3. PubMed ID: 8156218
[No Abstract] [Full Text] [Related]
36. Modeling and simulation of biopharmaceutical performance.
Zhang X; Lionberger RA
Clin Pharmacol Ther; 2014 May; 95(5):480-2. PubMed ID: 24747237
[TBL] [Abstract][Full Text] [Related]
37. When do differences in dissolution profiles predict clinical problems?
Ngo SN
J Clin Pharm Ther; 2007 Apr; 32(2):111-2. PubMed ID: 17381660
[No Abstract] [Full Text] [Related]
38. Bioequivalence Evaluations of Generic Dry Powder Inhaler Drug Products: Similarities and Differences Between Japan, USA, and the European Union.
Kuribayashi R; Yamaguchi T; Sako H; Takishita T; Takagi K
Clin Pharmacokinet; 2017 Mar; 56(3):225-233. PubMed ID: 27461251
[TBL] [Abstract][Full Text] [Related]
39. Requirements for submission of bioequivalence data; final rule. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2009 Jan; 74(11):2849-62. PubMed ID: 19385107
[TBL] [Abstract][Full Text] [Related]
40. Comparison of bioequivalence study regulatory requirements for human and veterinary drugs.
Grabowski T; Marczak M; Jaroszewski JJ; Whitmire M
Regul Toxicol Pharmacol; 2012 Nov; 64(2):233-42. PubMed ID: 22917973
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
